Skip to content
Subscribe
Newsletter
Advertise
MDA.org
Donate
Subscribe
Donate
Menu
Magazine
Current Issue
Past Issues
Featured Content
Topics
Advocacy
Finding a Diagnosis
Get Involved
Health
Inclusion
Independence
Lifestyle
News
Personal Stories
Science + Research
Diseases A-Z
Quest Blog
Podcast
Product Guide
Exon Skipping
Featured Article
A Good Beginning: Newborn Screening
By
Donna Albrecht
|
January 17, 2020
Blog Post
FDA Approves Sarepta Therapeutics’ Vyondys 53 for Treatment of DMD Amenable to Exon 53 Skipping
By
Jeanene Swanson
|
December 13, 2019
Blog Post
Five Questions with DMD Researcher Matthew Wood
By
Jeanene Swanson
|
October 23, 2019
Blog Post
NS Pharma Submits New Drug Application to FDA for Viltolarsen to Treat DMD Amenable to Exon 53 Skipping
By
Jeanene Swanson
|
October 7, 2019
Blog Post
Simply Stated: Is Muscular Dystrophy Genetic?
By
Jeanene Swanson
|
August 5, 2019
Blog Post
Audentes Therapeutics Announces Plans to Develop Gene-Targeted Therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1
By
Jeanene Swanson
|
April 11, 2019
Blog Post
Sarepta Therapeutics Announces Positive Interim Results from Study of Casimersen to Treat DMD Amenable to Exon 45 Skipping
By
Jeanene Swanson
|
April 4, 2019
Blog Post
FDA Accepts Sarepta Therapeutics’ New Drug Application (NDA) for Golodirsen to Treat DMD Amenable to Exon 53 Skipping
By
Jeanene Swanson
|
March 1, 2019
Blog Post
Wave Life Sciences Announces Phase 2/3 Duchenne Muscular Dystrophy Clinical Trial of Suvodirsen (WVE-210201) Selected for FDA Complex Innovative Trial Designs Pilot Program
By
Jeanene Swanson
|
January 8, 2019
« Previous
1
2
3
Skip to content
Open toolbar
Accessibility Tools
Accessibility Tools
Increase Text
Increase Text
Decrease Text
Decrease Text
Grayscale
Grayscale
High Contrast
High Contrast
Negative Contrast
Negative Contrast
Light Background
Light Background
Links Underline
Links Underline
Readable Font
Readable Font
Reset
Reset